Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2016 Aug 12:6:31421.
doi: 10.1038/srep31421.

Imaging biomarkers for steatohepatitis and fibrosis detection in non-alcoholic fatty liver disease

Rocío Gallego-Durán  1   2 , Pablo Cerro-Salido  3 , Emilio Gomez-Gonzalez  3 , María Jesús Pareja  4 , Javier Ampuero  1   2 , María Carmen Rico  1   2 , Rafael Aznar  5 , Eduardo Vilar-Gomez  1   2 , Elisabetta Bugianesi  6 , Javier Crespo  7 , Francisco José González-Sánchez  8 , Reyes Aparcero  9 , Inmaculada Moreno  10 , Susana Soto  11 , María Teresa Arias-Loste  7 , Javier Abad  12 , Isidora Ranchal  1   2 , Raúl Jesús Andrade  10 , Jose Luis Calleja  12 , Miguel Pastrana  13 , Oreste Lo Iacono  11 , Manuel Romero-Gómez  1   2
Affiliations

Imaging biomarkers for steatohepatitis and fibrosis detection in non-alcoholic fatty liver disease

Rocío Gallego-Durán et al. Sci Rep. .

Abstract

There is a need, in NAFLD management, to develop non-invasive methods to detect steatohepatitis (NASH) and to predict advanced fibrosis stages. We evaluated a tool based on optical analysis of liver magnetic resonance images (MRI) as biomarkers for NASH and fibrosis detection by investigating patients with biopsy-proven NAFLD who underwent magnetic resonance (MR) protocols using 1.5T General Electric (GE) or Philips devices. Two imaging biomarkers (NASHMRI and FibroMRI) were developed, standardised and validated using area under the receiver operating characteristic curve (AUROC) analysis. The results indicated NASHMRI diagnostic accuracy for steatohepatitis detection was 0.83 (95% CI: 0.73-0.93) and FibroMRI diagnostic accuracy for significant fibrosis determination was 0.85 (95% CI: 0.77-0.94). These findings were independent of the MR system used. We conclude that optical analysis of MRI has high potential to define non-invasive imaging biomarkers for the detection of steatohepatitis (NASHMRI) and the prediction of significant fibrosis (FibroMRI) in NAFLD patients.

PubMed Disclaimer

Figures

Figure 1
Figure 1. Analysis of diagnostic accuracy for NASH detection comparing NASHMRI and CK-18 (AUROC: 0.86; 95% CI: 0.76–0.96 vs. AUROC: 0.44; 95% CI: 0.29–0.60, respectively; p < 0.0001).
Figure 2
Figure 2. Analysis of diagnostic accuracy for significant fibrosis (≥F2) comparing FibroMRI, Sydney Index and NAFLD Fibrosis Score (AUROC: 0.85; 95% CI: 0.74–0.97 vs. AUROC: 0.69; 95% CI: 0.50–0.87 vs. AUROC: 0.76; 95% CI: 0.61–0.91, respectively; p < 0.001).
Figure 3
Figure 3. Analysis of diagnostic accuracy for significant fibrosis (≥F2) detection comparing Fibro-MRI and valid transient elastography measurements (AUROC: 0.95; 95% CI: 0.88–1.00 vs. AUROC: 0.91; 95% CI: 0.81–1.00, respectively; p = ns).
See this image and copyright information in PMC

References

    1. Chalasani N. et al. The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology. Gastroenterology 142, 1592–1609 (2012). - PubMed
    1. Wong V. W. et al. Prevalence of non-alcoholic fatty liver disease and advanced fibrosis in Hong Kong Chinese: a population study using proton-magnetic resonance spectroscopy and transient elastography. Gut 2012 61, 409–415 (2012). - PubMed
    1. Singh S. et al. Fibrosis progression in nonalcoholic fatty liver vs nonalcoholic steatohepatitis: a systematic review and meta-analysis of paired-biopsy studies. Clin Gastroenterol Hepatol 13, 643–54 (2015). - PMC - PubMed
    1. Bellentani S. & Marino M. Epidemiology and natural history of non-alcoholic fatty liver disease (NAFLD). Ann. Hepatol. 8, S4–S8 (2009). - PubMed
    1. affy G., Brunt E. M. & Caldwell S. H. Hepatocellular carcinoma in non-alcoholic fatty liver disease: an emerging menace. J. Hepatol. 56, 1384–1391 (2012). - PubMed

Publication types

MeSH terms